Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Clarus Therapeutics Holdings Inc. (CRXT)

   0 (0%) 12-31 19:00
Open: Pre. Close:
High: Low:
Volume: Market Cap: 0M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.631 - 1.641 1.641 - 1.65
Low: 1.478 - 1.489 1.489 - 1.499
Close: 1.563 - 1.579 1.579 - 1.595

Technical analysis

as of: 2022-01-21 4:25:44 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 4.38     One year: 6.02
Support: Support1: 1.49    Support2: 1.24
Resistance: Resistance1: 3.75    Resistance2: 5.15
Pivot: 2.08
Moving Average: MA(5): 1.62     MA(20): 2.36
MA(100): 4.91     MA(250):
MACD: MACD(12,26): -0.69     Signal(9): -0.67
Stochastic oscillator: %K(14,3): 4.72     %D(3): 6.05
RSI: RSI(14): 23.78
52-week: High: 31.24  Low: 1.49  Change(%): -84.5
Average Vol(K): 3-Month: 1910  10-Days: 763

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CRXT has closed above bottom band by 22.3%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 18 Jan 2022
Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief - GlobeNewswire

Fri, 14 Jan 2022
How Does Clarus Therapeutics Holdings Inc (CRXT) Stock Rank on Wall Street Friday? - InvestorsObserver

Mon, 27 Dec 2021
Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Tue, 07 Dec 2021
Clarus Therapeutics Announces Closing of Approximately $15 - GlobeNewswire

Tue, 30 Nov 2021
Clarus Therapeutics: Advancing Androgen Replacement And Metabolic Therapies - Seeking Alpha

Fri, 05 Nov 2021
What Percentage Of Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Shares Do Insiders Own? - Nasdaq

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Neutral
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange: 
Sector: 
Industry: 
Shares Out. (M) 24
Shares Float (M) 1
% Held by Insiders 7.83
% Held by Institutions 95.10
Shares Short (K) 209
Shares Short P. Month (K) 332

Stock Financials

EPS -26.017
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) -1.170
Profit Margin
Operating Margin -343.61
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth 92.7
Gross Profit (p.s.) -0.097
Sales Per Share 0.492
EBITDA (p.s.) -1.690
Qtrly Earnings Growth
Operating Cash Flow (M) -40
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -0.06
PEG Ratio
Price to Book value -1.35
Price to Sales 3.21
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.